Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 27;19(3):673. doi: 10.3390/ijms19030673

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Preservation of paracellular flux by Rhinosectan^® between the apical and basolateral compartments of MucilAir. Preservation of paracellular flux reflects the integrity of the mucosal barrier. Lucifer yellow (LY) permeability after 2 h of pre-treatment with Rhinosectan^® (30 µL) and 16 h of exposure to pro-inflammatory compounds (LY flux (%) values). LY Flux = (RFUbl/RFUap) × 100, where RFUbl are fluorescent units detected at the basolateral compartment and RFUap are units detected at the apical part compartment. CN: negative control (pre-treatment with saline solution), without presence of pro-inflammatory compounds; TNF/LPS: pre-treatment with saline solution and exposure to pro-inflammatory compounds (TNF-α 500 ng/ml plus LPS from Pseudomonas aeruginosa 10, 0.2 mg/mL); RTAN: pre-treatment with Rhinosectan^® (30 µL) and 16 h of exposure to pro-inflammatory compounds; RCORT: pre-treatment with Rhinocort^® spray (budesonide) (30 µL) and 16 h of exposure to pro-inflammatory compounds [1].